276 related articles for article (PubMed ID: 16917213)
21. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
Coley HM; Sarju J; Wagner G
J Med Chem; 2008 Jan; 51(1):135-41. PubMed ID: 18072719
[TBL] [Abstract][Full Text] [Related]
23. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
24. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation.
Cemazar M; Pipan Z; Grabner S; Bukovec N; Sersa G
Anticancer Res; 2006; 26(3A):1997-2002. PubMed ID: 16827135
[TBL] [Abstract][Full Text] [Related]
26. Platinum-based anticancer agents: innovative design strategies and biological perspectives.
Ho YP; Au-Yeung SC; To KK
Med Res Rev; 2003 Sep; 23(5):633-55. PubMed ID: 12789689
[TBL] [Abstract][Full Text] [Related]
27. No correlation between GSH levels in human cancer cell lines and the cell growth inhibitory activities of platinum diamine complexes.
Boubakari ; Bracht K; Neumann C; Grünert R; Bednarski PJ
Arch Pharm (Weinheim); 2004 Dec; 337(12):668-71. PubMed ID: 15614830
[TBL] [Abstract][Full Text] [Related]
28. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
Oprea A; Bazzazi H; Kangarloo B; Wolff JE
Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
[TBL] [Abstract][Full Text] [Related]
29. Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance.
Margiotta N; Natile G; Capitelli F; Fanizzi FP; Boccarelli A; De Rinaldis P; Giordano D; Coluccia M
J Inorg Biochem; 2006 Nov; 100(11):1849-57. PubMed ID: 16959321
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of the antitumor activity of newly developed platinum analogs in lung cancer using the colony assay].
Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Yamashita H; Kozuka A; Moritaka T; Uji H; Kiura K; Mima Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):427-30. PubMed ID: 2539056
[No Abstract] [Full Text] [Related]
31. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
Dedon PC; Borch RF
Biochem Pharmacol; 1987 Jun; 36(12):1955-64. PubMed ID: 2954556
[TBL] [Abstract][Full Text] [Related]
32. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
33. Drug transporters of platinum-based anticancer agents and their clinical significance.
Burger H; Loos WJ; Eechoute K; Verweij J; Mathijssen RH; Wiemer EA
Drug Resist Updat; 2011 Feb; 14(1):22-34. PubMed ID: 21251871
[TBL] [Abstract][Full Text] [Related]
34. Effect of glutathione-modulating compounds on platinum compounds-induced cytotoxicity in human glioma cell lines.
Iida M; Doi H; Asamoto S; Sugiyama H; Sakagami H; Kuribayashi N; Takeda M; Okamura Y; Matsumoto K
Anticancer Res; 1999; 19(6B):5383-4. PubMed ID: 10697565
[TBL] [Abstract][Full Text] [Related]
35. In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands.
Momekov G; Ferdinandov D; Bakalova A; Zaharieva M; Konstantinov S; Karaivanova M
Arch Toxicol; 2006 Sep; 80(9):555-60. PubMed ID: 16485120
[TBL] [Abstract][Full Text] [Related]
36. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
37. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
38. In vitro biochemical and pharmacological evaluation of a novel cytotoxic dinuclear platinum(II) complex with 3-amino-5-methyl-5-phenylhydantoin.
Momekov GTs; Ugrinova I; Pasheva EA; Bakalova AG; Varbanov HP; Ferdinandov DV; Ivanov DS; Konstantinov SM
Ann N Y Acad Sci; 2009 Aug; 1171():649-58. PubMed ID: 19723116
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
40. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]